Search Result

Results for "

motor effects

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (3) Apoptosis (1) Autophagy (1) Caspase (1) Cholinesterase (ChE) (1) Dopamine Receptor (4) Dopamine Transporter (1) Endogenous Metabolite (1) Interleukin Related (1) JNK (1) mAChR (1) MAP4K (1) mGluR (1) Mitochondrial Metabolism (1) Monoamine Oxidase (1) Neurokinin Receptor (2) NO Synthase (3) Nuclear Hormone Receptor 4A/NR4A (1) Serotonin Transporter (1) Sigma Receptor (4) α-synuclein (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (5) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (20)

By Targets:

Adenosine Receptor (1)

Akt (3)

Apoptosis (1)

Autophagy (1)

Caspase (1)

Cholinesterase (ChE) (1)

Dopamine Receptor (4)

Dopamine Transporter (1)

Endogenous Metabolite (1)

Interleukin Related (1)

JNK (1)

mAChR (1)

MAP4K (1)

mGluR (1)

Mitochondrial Metabolism (1)

Monoamine Oxidase (1)

Neurokinin Receptor (2)

NO Synthase (3)

Nuclear Hormone Receptor 4A/NR4A (1)

Serotonin Transporter (1)

Sigma Receptor (4)

α-synuclein (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (5)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (20)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18100A

PRE-084 hydrochloride 5+ Cited Publications	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-B0411

Domperidone 5 Publications Verification R33812	Dopamine Receptor	Neurological Disease
Domperidone (R33812) is an orally active and selective dopamine-2 receptor antagonist. Domperidone acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine .

HY-B0411A

Domperidone monomaleate 5 Publications Verification R33812 monomaleate	Dopamine Receptor	Neurological Disease
Domperidone (R33812) monomaleate is an orally active and selective dopamine-2 receptor antagonist. Domperidone monomaleate acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine .

HY-136281

DuP 734	Sigma Receptor	Neurological Disease
DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT2 receptor ligand with weak affinity for D2 receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics .

HY-118406A

Ethybenztropine hydrochloride Ponalid hydrochloride; UK 738 hydrochloride	mAChR	Neurological Disease
Ethybenztropine hydrochloride (Ponalid hydrochloride) is an anticholinergic drug with antiparkinsonian activity. Ethybenztropine hydrochloride may also have dopamine reuptake inhibitory effects. Ethybenztropine hydrochloride is used to improve motor symptoms in patients with Parkinson's disease. Ethybenztropine hydrochloride exerts its inhibitory effects by regulating the balance of neurotransmitters .

HY-18100

PRE-084	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-124406

A-794282	mGluR	Neurological Disease
A-794282 is an antagonist with analgesic activity, selectively targeting to mGlu1 receptor that significantly reduces pain behaviors in a postoperative pain model, but motor side effects may occur at higher doses .

HY-14408

Lu AA47070	Adenosine Receptor	Neurological Disease
Lu AA47070 is a phosphonooxymethylene prodrug of a potent and selective Adenosine A2A receptor antagonist. Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade .

HY-18100AR

PRE-084 hydrochloride (Standard)	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 (hydrochloride) (Standard) is the analytical standard of PRE-084 (hydrochloride). This product is intended for research and analytical applications. PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-B0411S

Domperidone-d6	Dopamine Receptor	Neurological Disease
Domperidone-d₆ is the deuterium labeled Domperidone. Domperidone (R33812) is a selective dopamine-2 receptor antagonist. Domperidone acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine[1][2].

HY-B0411R

Domperidone (Standard)	Dopamine Receptor	Neurological Disease
Domperidone (Standard) is the analytical standard of Domperidone. This product is intended for research and analytical applications. Domperidone (R33812) is an orally active and selective dopamine-2 receptor antagonist. Domperidone acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine .

HY-76201

Dexrazoxane hydrochloride Maximum Cited Publications 10 Publications Verification ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases .

HY-107811

Harmol 1 Publications Verification	Monoamine Oxidase Autophagy Apoptosis α-synuclein	Cardiovascular Disease Neurological Disease Cancer
Harmol is a TFEB activator, an orally active monoamine oxidase inhibitor that has anti-tumor, anti-depressant, and anti-aging effects. Harmol can induce cell mitosis, autophagy and apoptosis. Harmol promotes the degradation of α-synuclein through the regulation of the autophagy-lysosomal pathway, improving motor deficits in mouse models of Parkinson's disease .

HY-117512

UWA-101 hydrochloride	Dopamine Transporter Serotonin Transporter	Neurological Disease
UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC₅₀ values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .

HY-W011978

N-Acetyl-L-tryptophan	Endogenous Metabolite Mitochondrial Metabolism Neurokinin Receptor Caspase Interleukin Related	Neurological Disease Inflammation/Immunology
N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases .

HY-115860

TAS-4	Others	Neurological Disease
TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .

HY-155659

4A7C-301	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease
4A7C-301 is a Nurr1 agonist with robust neuroprotective effects in vitro. 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models. 4A7C-301 can be used for the research of Parkinson’s disease .

HY-B0824A

(1R)-cis-Bifenthrin	Others	Others
(1R)-cis-Bifenthrin is a widely used pyrethroid pesticide with activity that reduces motor coordination. (1R)-cis-Bifenthrin has a significant impact on the motor function of ParK_in-/- mice, as shown by increased pole climbing time and wheel running Time decreases. Exposure of (1R)-cis-Bifenthrin resulted in a significant reduction in tyrosine hydroxylase-positive cell counts and protein expression. (1R)-cis-Bifenthrin caused increased expression of mitophagy-related proteins LC3B and p62. (1R)-cis-Bifenthrin has a lower binding energy with transferrin and transferrin receptor 2, showing stronger interactions. The biological effects of (1R)-cis-Bifenthrin show relationships with mitophagy and ferroptosis-related pathways .

HY-162922

MAP4K4-IN-6	MAP4K JNK	Neurological Disease
MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC₅₀: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS) .

HY-143464

BChE-IN-4	Cholinesterase (ChE)	Neurological Disease
BChE-IN-4 is a potent and cross the blood-brain barrier BChE inhibitor. BChE-IN-4 attenuates learning and memory deficits caused by cholinergic deficit in mouse model. BChE-IN-4 has the potential for the research of alzheimer’s disease .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Others Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

Cat. No.	Product Name	Target	Research Area